论文部分内容阅读
单纯性肥胖１０８例采取随机、双盲分成两组各５４例。年龄、性别、体重程度无明显差别，有可比性。治疗组口服马吲跺１ｍｇ，２次／日，对照组口服芬氟拉明２０ｍｇ，３次／日；疗程８周。结果：治疗组体重平均下降５，１４±１．６５ｋｇ、总有效率１００％（有效、显效率８８．９％）；对照组为４．２８±１．４８及９２．６％（７２．２％）．两组均有降低血压、血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、血糖、胰岛素、生长激素和升高超氧化物歧化酶－锌－铜作用。但治疗组对ＴＣ、ＴＧ、收缩压、舒张压、生长激素、胰岛素及口服葡萄糖耐量试验后胰岛素及血糖面积均优于对照组（Ｐ＜０．０１和Ｐ＜０．０５）。显示马吲哚抗胰岛素抵抗更优于芬氟拉明。此外，马吲哚有克服嗜睡、胃肠道副反应少的作用。马吲哚在减肥同时对冠心病防治更有利。
108 cases of simple obesity to take a randomized, double-blind divided into two groups of 54 cases. Age, sex, weight, no significant difference between the degree of comparability. Treatment group oral Ma indole 1mg, 2 times / day, the control group oral fenfluramine 20mg, 3 times / day; course of treatment for 8 weeks. Results: The average body weight of the treatment group decreased by 5,14 ± 1.65kg, the total effective rate was 100% (effective, effective rate was 88.9%); the control group was 4.28 ± 1.48 and 92.6% (72.2% %). Lowering blood pressure, serum total cholesterol (TC), triglyceride (TG), blood sugar, insulin, growth hormone and increasing superoxide dismutase-zinc-copper effect were found in both groups. However, the TC and TG, systolic blood pressure, diastolic blood pressure, growth hormone, insulin and oral glucose tolerance test in the treatment group were better than those in the control group (P <0.01 and P <0.05). Indomethacin resistance to insulin resistance is better than fenfluramine. In addition, mazindol has to overcome lethargy, gastrointestinal side effects of less. Mazindol at the same time in the prevention and treatment of coronary heart disease more favorable.